Pre-Diagnosis Exercise and Cardiovascular Events in Primary Breast Cancer: Women's Health Initiative.
BMI, body mass index
CRF, cardiorespiratory fitness
CT, clinical trial
CVE, cardiovascular event
HF, heart failure
HT, hormone therapy
IQR, interquartile range
MET, metabolic equivalent task
MI, myocardial infarction
OS, observational study
PAD, peripheral arterial disease
TIA, transient ischemic attack
WHI, Women’s Health Initiative
Women’s Health Initiative
breast cancer
cardiovascular disease
cardiovascular events
exercise
physical activity
survivors
Journal
JACC. CardioOncology
ISSN: 2666-0873
Titre abrégé: JACC CardioOncol
Pays: United States
ID NLM: 101761697
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
12
06
2019
revised:
12
08
2019
accepted:
16
08
2019
entrez:
16
8
2021
pubmed:
24
9
2019
medline:
24
9
2019
Statut:
epublish
Résumé
The purpose of this study was to investigate whether pre-diagnosis exercise reduces the risk of subsequent cardiovascular events (CVEs) in women with primary breast cancer. Cardiovascular disease (CVD) is the leading nonmalignant cause of death in patients with cancer, and it is the leading cause of death in women with primary breast cancer who are older than 65 years of age. Using a prospective design, 4,015 patients with confirmed diagnosis of primary breast cancer enrolled in the Women's Health Initiative (WHI) completed a self-report questionnaire assessing leisure-time physical activity (i.e., exercise) in metabolic equivalent task (MET) hours per week. Age- and multivariable-adjusted Cox proportional hazards models were used to estimate associations between pre-diagnosis exercise and new-onset CVEs (i.e., heart failure [HF], myocardial infarction [MI], angina, coronary revascularization, peripheral arterial disease [PAD], carotid artery disease, transient ischemic attack [TIA], stroke, and cardiovascular death). Median follow-up was 12.7 years and 8.2 years for cardiovascular disease (CVD) mortality and CVEs, respectively, with 324 CVEs, including 89 MIs, 49 new diagnoses of HF, and 215 CVD deaths. In multivariable analysis, the incidence of composite CVEs decreased across increasing total MET h/week categories (p = 0.016). Compared with <2.5 MET-hours per week, the adjusted hazard ratio (HR) was 0.80 (95% confidence interval [CI]: 0.59 to 1.09) for 2.5 to <8.6 MET h/week; 0.9 (95% CI: 0.64 to 1.17) for 8.6 to <18 MET h/week; and 0.63 (95% CI: 0.45 to 0.88) for ≥18 MET h/week. Pre-diagnosis exercise exposure is associated with a significant graded reduction in subsequent CVEs in long-term survivors of primary breast cancer.
Sections du résumé
OBJECTIVES
OBJECTIVE
The purpose of this study was to investigate whether pre-diagnosis exercise reduces the risk of subsequent cardiovascular events (CVEs) in women with primary breast cancer.
BACKGROUND
BACKGROUND
Cardiovascular disease (CVD) is the leading nonmalignant cause of death in patients with cancer, and it is the leading cause of death in women with primary breast cancer who are older than 65 years of age.
METHODS
METHODS
Using a prospective design, 4,015 patients with confirmed diagnosis of primary breast cancer enrolled in the Women's Health Initiative (WHI) completed a self-report questionnaire assessing leisure-time physical activity (i.e., exercise) in metabolic equivalent task (MET) hours per week. Age- and multivariable-adjusted Cox proportional hazards models were used to estimate associations between pre-diagnosis exercise and new-onset CVEs (i.e., heart failure [HF], myocardial infarction [MI], angina, coronary revascularization, peripheral arterial disease [PAD], carotid artery disease, transient ischemic attack [TIA], stroke, and cardiovascular death).
RESULTS
RESULTS
Median follow-up was 12.7 years and 8.2 years for cardiovascular disease (CVD) mortality and CVEs, respectively, with 324 CVEs, including 89 MIs, 49 new diagnoses of HF, and 215 CVD deaths. In multivariable analysis, the incidence of composite CVEs decreased across increasing total MET h/week categories (p = 0.016). Compared with <2.5 MET-hours per week, the adjusted hazard ratio (HR) was 0.80 (95% confidence interval [CI]: 0.59 to 1.09) for 2.5 to <8.6 MET h/week; 0.9 (95% CI: 0.64 to 1.17) for 8.6 to <18 MET h/week; and 0.63 (95% CI: 0.45 to 0.88) for ≥18 MET h/week.
CONCLUSION
CONCLUSIONS
Pre-diagnosis exercise exposure is associated with a significant graded reduction in subsequent CVEs in long-term survivors of primary breast cancer.
Identifiants
pubmed: 34396161
doi: 10.1016/j.jaccao.2019.08.014
pii: S2666-0873(19)30036-5
pmc: PMC8352124
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-50Subventions
Organisme : NHLBI NIH HHS
ID : HHSN268201100001I
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA173642
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100004I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100046C
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100003C
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100002C
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA173642
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100003I
Pays : United States
Organisme : NHLBI NIH HHS
ID : HHSN268201100002I
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100001C
Pays : United States
Organisme : WHI NIH HHS
ID : HHSN268201100004C
Pays : United States
Informations de copyright
© 2019 The Authors.
Références
J Natl Cancer Inst. 2013 Dec 4;105(23):1821-32
pubmed: 24151326
Control Clin Trials. 1998 Feb;19(1):61-109
pubmed: 9492970
Am J Health Behav. 2007 Mar-Apr;31(2):193-202
pubmed: 17269909
JAMA. 2003 Sep 10;290(10):1331-6
pubmed: 12966124
J Clin Oncol. 2001 Feb 1;19(3):657-65
pubmed: 11157015
Breast Cancer Res. 2011 Jun 20;13(3):R64
pubmed: 21689398
J Am Coll Cardiol. 2014 Aug 5;64(5):472-81
pubmed: 25082581
Cancer. 2017 Jul 1;123(13):2432-2443
pubmed: 28267199
J Clin Oncol. 2014 Nov 10;32(32):3643-50
pubmed: 25311213
J Clin Oncol. 2015 Jun 10;33(17):1918-27
pubmed: 25918291
J Clin Oncol. 2016 Aug 10;34(23):2743-9
pubmed: 27217451
Cancer Prev Res (Phila). 2013 Sep;6(9):925-37
pubmed: 23842792
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Neoplasma. 2017;64(1):92-100
pubmed: 27881009
Med Sci Sports Exerc. 1993 Jan;25(1):71-80
pubmed: 8292105
J Clin Oncol. 2007 Oct 1;25(28):4396-404
pubmed: 17785708
CMAJ. 2006 Jul 4;175(1):34-41
pubmed: 16818906